ASEAN Covid-19 Table – 19 January 2022
Asean as a whole has reported more than 15.8 million COVID-19 cases. Of this, more than 810,000 are active cases as of January 19.
The coronavirus COVID-19 is affecting 219 countries and territories around the world and 2 international conveyances.
Here we provide updated information on cases in ASEAN, comprising new cases, total cases, new deaths and total deaths.
Booster mix effective against Omicron, study shows in Thailand
The Department of Medical Sciences has found that administering an mRNA-based vaccine such as Pfizer or Moderna as a booster after initial doses of old-technology vaccines like Sinovac and/or AstraZeneca produces a high level of immunity against both the Delta and Omicron coronavirus variants.
Latest official COVID-19 data close x Confirmed 4,272,421
Source: Indonesian government Last Update: Jan 18, 2022
<Jakarta braces for impending ‘battle’ with Omicron A woman receives a booster dose of the Pfizer COVID-19 vaccine in Jakarta on Jan. 12, 2022. (AFP/Adek Berry) Share Nina A. Loasana (The Jakarta Post) PREMIUM Jakarta ● Tue, January 18, 2022 Jakartans are being called upon to be more vigilant and consider once again the possibility of working from home, after authorities flagged the city as the “first battleground” in the fight against the Omicron COVID-19 strain, amid worrying predictions of a third infection wave in the coming weeks.
This article was published in thejakartapost.com with the title “Jakarta braces for impending ‘battle’ with Omicron”.
Lao factory producing Molacovir for treatment of Covid patients
State Enterprise Pharmaceutical Factory No. 3 in Vientiane is manufacturing a revolutionary new drug named Molacovir for use in the early stages of Covid-19.
The drug is administered orally and under Lao copyright is known as Molacovir.
The new drug formula was first used in the treatment of influenza and was developed by scientists at Emory University in the United States.
The US Food and Drug Administration (FDA) has approved molnupiravir for use in the early treatment of Covid-19 patients, raising confidence in the future reduction of the high mortality rate from the virus